Shuai Liu1,2,3,4, Zheng Feng4,5, Hao Wen4,5, Zhaoxia Jiang4,6, Herong Pan1,2,3,4, Yu Deng5,7, Lei Zhang5,7, Xingzhu Ju4,5, Xiaojun Chen4,5, Xiaohua Wu8,9. 1. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Center for Biomedical Imaging, Fudan University, Shanghai, China. 3. Shanghai Engineering Research Center of Molecular Imaging Probes, Fudan University, Shanghai, China. 4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 5. Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. 6. Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China. 7. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. 8. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. docwuxh@hotmail.com. 9. Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. docwuxh@hotmail.com.
Abstract
PURPOSE: This study aimed to explore the clinical and prognostic significance of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in epithelial ovarian cancer (EOC). METHODS: We retrospectively investigated 48 EOC patients who underwent preoperative 18F-FDG PET/CT and primary cytoreductive surgery at our hospital between January 2010 and June 2015. None of these patients received neoadjuvant chemotherapy. PET/CT parameters including the maximum and average standardized uptake value (SUVmax, SUVavg), the metabolic tumor volume (MTV) were measured. Tumor proliferation marker Ki67 was evaluated using immunohistochemistry. The relationships between the PET/CT parameters and chemosensitivity, tumor proliferation, and overall survival (OS) were analyzed, respectively. RESULTS: The median (range) SUVmax, SUVavg, and MTV values were 11.42 (3.14-20.20), 4.8 (2.55-9.47), and 150.11 (0.19-792.46), respectively. Overall, 93.8% (45/48) of patients had high-grade serous ovarian cancer. The SUVmax value had a positive correlation with the Ki67 index (P = 0.030, r = 0.314), and a higher SUVmax level was associated with chemosensitivity (P = 0.026). However, neither SUVavg nor MTV had associations with the patients' clinicopathological parameters. None of these three PET/CT parameters were found to be potential predictors of OS. CONCLUSIONS: Preoperative 18F-FDG PET/CT had a predictive value on chemosensitivity and proliferation after primary debulking surgery in EOC patients noninvasively.
PURPOSE: This study aimed to explore the clinical and prognostic significance of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in epithelial ovarian cancer (EOC). METHODS: We retrospectively investigated 48 EOC patients who underwent preoperative 18F-FDG PET/CT and primary cytoreductive surgery at our hospital between January 2010 and June 2015. None of these patients received neoadjuvant chemotherapy. PET/CT parameters including the maximum and average standardized uptake value (SUVmax, SUVavg), the metabolic tumor volume (MTV) were measured. Tumor proliferation marker Ki67 was evaluated using immunohistochemistry. The relationships between the PET/CT parameters and chemosensitivity, tumor proliferation, and overall survival (OS) were analyzed, respectively. RESULTS: The median (range) SUVmax, SUVavg, and MTV values were 11.42 (3.14-20.20), 4.8 (2.55-9.47), and 150.11 (0.19-792.46), respectively. Overall, 93.8% (45/48) of patients had high-grade serous ovarian cancer. The SUVmax value had a positive correlation with the Ki67 index (P = 0.030, r = 0.314), and a higher SUVmax level was associated with chemosensitivity (P = 0.026). However, neither SUVavg nor MTV had associations with the patients' clinicopathological parameters. None of these three PET/CT parameters were found to be potential predictors of OS. CONCLUSIONS: Preoperative 18F-FDG PET/CT had a predictive value on chemosensitivity and proliferation after primary debulking surgery in EOC patients noninvasively.
Authors: Francesco Fanfani; Giorgia Monterossi; Anna Fagotti; Valerio Gallotta; Barbara Costantini; Giuseppe Vizzielli; Marco Petrillo; Maria Vittoria Carbone; Giovanni Scambia Journal: Ann Surg Oncol Date: 2014-08-26 Impact factor: 5.344
Authors: Jeong Won Lee; Arthur Cho; Jae-Hoon Lee; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang Journal: Eur J Nucl Med Mol Imaging Date: 2014-05-23 Impact factor: 9.236
Authors: P L Jager; M A de Korte; M N Lub-de Hooge; A van Waarde; K P Koopmans; P J Perik; E G E de Vries Journal: Cancer Imaging Date: 2005-11-23 Impact factor: 3.909
Authors: Hyun Ju Lee; Jong Jin Lee; Jeong Yeol Park; Jong Hyeok Kim; Yong Man Kim; Young Tak Kim; Joo Hyun Nam Journal: J Gynecol Oncol Date: 2017-07 Impact factor: 4.401
Authors: Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2021-07-03 Impact factor: 9.236